Pando Software Begins Pre-Registration of Three New P2E Pandonia Universes
28.4.2022 07:24:00 EEST | Business Wire | Press release
The new P2E Pandonia Universe starts pre-registration ahead of its simultaneous worldwide release. The three Pandonia Universes include ‘Pandonia Arena,’ ‘Guardians of Pandonia,’ and ‘Dragons of Pandonia.’ Pre-registration is available now on https://pandonia.co.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006357/en/
Three new P2E Pandonia Universes have started pre-registration ahead of their worldwide release. The three Pandonia Universes include ‘Pandonia Arena,’ ‘Guardians of Pandonia,’ and ‘Dragons of Pandonia.’ Pre-registration is available now on the official website. (Graphic: Business Wire)
‘Pandonia Arena’ with unique heroes
‘Pandonia Arena’ was issued as non-fungible tokens (NFT) for heroes with distinctive visuals and unique skills. The control method that allows anyone to play easily, such as battle royale mode, big boss mode, and crown mode, is a huge advantage. The global No.1 Arcade NFT-based P2E game ‘Pandonia Arena’ will be released in May.
New collectible RPG, P2E game ‘Guardians of Pandonia’
‘Guardians of Pandonia’ is a mobile collectible RPG where you can create your own team with up to six characters and enjoy adventures, raids, and PvP content. In particular, there are high expectations for this new collectible P2E game in Japan, so it is planned to be released in June.
MMORPG 'Dragons of Pandonia,' a story created with a variety of dragons
‘Dragons of Pandonia’ is an MMORPG focused on dragons. It is the P2E-based MMORPG where users write their own huge and powerful stories relying on five different occupation types and various dragons. Development is underway aiming at a global launch in July.
Special benefits for pre-registrants of the three Pandonia Universes
For pre-registered users, Pando Software has announced that it will provide game-related privileges along with an airdrop event in which 10,000 mPANDO will be drawn and distributed, fitting the game's official release date.
In the three new Pandonia Universes, users can acquire mPANDO through gameplay as well as through other games currently being serviced by Pando Software. mPANDO is a MainNet coin and is designed to be used for various in-game applications.
Starting with the ‘Legend of Pandonia’ as its first P2E project in 2022, Pando Software has continued with the ‘I Love Pandonia’ release to the global market.
The detailed schedule and news about the three Pandonia Universes can be checked on the official website (https://pandonia.co).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006357/en/
Contact information
Pando Software Inc
Lucia Tanti
+82-70-5100-0815
pr@pandosoft.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom